MedTrace Logo

Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

NCT03324425 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-02-27

No results posted yet for this study

Summary

This study recruits patients with metastatic breast cancer who have progressed on their current regimen of dual anti-HER2 therapy. This study evaluates whether or not the addition of simvastatin to the dual anti-HER2 therapy regimen helps make the tumor respond to the anti-HER2 therapy again. All participants will receive simvastatin in combination with their current anti-HER2 therapy regimen.

Conditions

  • Breast Cancer Stage IV

Interventions

DRUG

Simvastatin 80mg

Participants will receive simvastatin 80 mg by mouth daily at bedtime

Sponsors & Collaborators

  • Baylor Breast Care Center

    lead OTHER

Principal Investigators

  • Mothaffar Rimawi, MD · Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-04
Primary Completion
2028-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03324425 on ClinicalTrials.gov